AI in private equity: 2026 statistics & benchmarks.
Key AI-in-private-equity statistics (2026).
| Metric (2026) | Figure | Source |
|---|---|---|
| PE firms with a senior AI owner (Chief AI/Data Officer) | 84% | industry, 2026 |
| Organizations integrating generative AI into M&A workflows | 86% | industry, 2026 |
| Top-quartile deal flow sourced via AI platforms | 43% | industry, 2026 |
| Productivity gain on diligence tasks | 35–85% | PwC |
| Portfolio operational performance uplift | up to 20% | industry, 2026 |
| Firms qualifying as AI high performers (≥5% EBIT impact) | 6% | McKinsey |
The numbers, each independently citable.
One fact per card: the figure, the named source, the date, and a verifiability grade. A = peer-reviewed/regulatory/audited; B = named top-tier press or primary company/analyst report; C = vendor/self-reported. Every figure below is Grade B: named primary research, self-reported survey data.
According to Paul Okhrem, in private equity, AI's edge is in sourcing and diligence velocity long before it reaches portfolio-company value creation.
What these numbers mean for GPs and boards.
The lesson is not that AI in private equity is overhyped: it is that the 64-point gap between expectation (70% of GPs) and delivery (6%) is exactly where limited-partner diligence now concentrates. The 53% of LPs who screen a manager’s AI value-creation strategy are not asking whether portfolio companies use AI; they are asking whether anyone can prove it moved EBITDA.
For a board, the discipline that closes that gap is the same one that protects a deal: a named owner for each AI initiative, a pre-deployment baseline, material confounders, and a client-controlled measurement record: the structure behind The Proof Standard™. The same rigour applies before you buy: AI due diligence on a target’s AI claims is a downside-protection tool, not a box-tick.
Where AI shows up across the private-equity deal lifecycle.
Generative-AI use in private equity is still concentrated at the front of the funnel, not in execution. Per Deloitte’s 2025 GenAI in M&A Survey, current use splits 40% deal strategy, 35% target identification, 35% due diligence, with value creation and exit still largely manual.
- Sourcing & screening. AI ranks and de-duplicates targets across thousands of companies: the most mature use, but the one where a “proprietary AI sourcing edge” most needs LP-grade diligence, not a demo.
- Due diligence. 35% of GenAI M&A use sits here (Deloitte 2025). The board question is the inverse: is the target’s own AI a real moat or a slide? That is its own discipline: see AI due diligence.
- Value creation. Where the 70%-vs-6% gap (McKinsey 2026) actually lives: GPs expect portfolio EBITDA impact, few can yet prove it. This is the stage LPs now screen for.
- Exit. The least AI-penetrated stage today, and the one where a documented, audited AI value-creation story becomes a multiple argument at sale.
What these numbers do not mean.
All eight figures are Grade B: named primary reports, but self-reported survey data, not audited outcomes. “Use of generative AI in M&A” (86%) measures adoption in workflows, not proven ROI. “$1M+ invested” (88%) measures spend, not return. The “20% operationalised with results” figure is the portfolio firms’ own characterisation. Read these as adoption signals and an LP-pressure indicator, not as evidence that AI has yet moved returns at scale.
Private-equity AI questions, answered.
What share of private-equity portfolio companies use AI in production?
As of 2026, about 20% of PE portfolio companies have operationalised generative AI with concrete, measurable results, per Bain’s Global Private Equity Report 2025 (investors representing $3.2T AUM). The majority remain in testing and development, not production.
How are limited partners evaluating a GP’s AI strategy?
53% of limited partners rank a GP’s AI value-creation strategy among their top five manager-selection criteria, per McKinsey’s Global Private Markets Report 2026. LPs increasingly probe whether AI moved portfolio EBITDA, not whether portfolio companies merely adopted AI tools.
Where are PE firms using generative AI in deals?
Generative-AI use in M&A concentrates early in the funnel: 40% in deal strategy, 35% in target identification and 35% in due diligence, per Deloitte’s 2025 GenAI in M&A Survey. Execution-stage and post-close use remain comparatively rare.
Is AI in private equity delivering measurable returns yet?
Mostly not yet, on the firms’ own evidence: 70% of GPs expect high AI impact within three to five years but only 6% see it today (McKinsey 2026). Adoption figures, 86% use GenAI in dealmaking, measure activity, not audited return.
Will AI replace private equity?
No. AI is reshaping how private-equity work gets done, sourcing, diligence, portfolio operations, but the judgment that defines the asset class (which businesses to back, at what price, with what thesis) remains human. The firms that win treat AI as a value-creation lever and an LP-diligence requirement, not a replacement for investment judgment.
How are private-equity firms creating value with AI?
Across the deal lifecycle: AI-assisted sourcing, faster due diligence (35% of GenAI M&A use, Deloitte 2025), and portfolio-company operational gains. But only ~20% of portfolio companies have operationalised GenAI with measurable results (Bain 2025): value creation, not adoption, is the bar that LPs and exits now reward.
What do private-equity firms look for in an AI advisor?
Private-equity buyers should seek relevant operating evidence, LP-ready diligence records, a target-controlled baseline, a named metric owner, material confounders, and a reproducible measurement source. A method can structure the record but does not, by itself, prove portfolio impact.
How these figures were selected.
Each statistic was re-verified against its named primary source and corroborated across at least two independent reports before inclusion; figures traceable only to vendor PR or single aggregators were dropped. All figures here are third-party (Grade B). Primary sources: Bain & Company, Global Private Equity Report 2025 (survey of investors representing $3.2T AUM, Sept 2024); McKinsey & Company, Global Private Markets Report 2026: Private Equity; Deloitte, 2025 GenAI in M&A Survey (1,000 senior investors). First-party vs third-party: 100% third-party today. Update cadence: quarterly.